A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

IsraelActive Not RecruitingPHASE3

Conditions

Primary IgA Nephropathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona, United States

  • Kaiser Permanente, San Diego, California, United States

  • North America Research Institute, San Dimas, California, United States

  • University of Colorado Anschutz, Aurora, Colorado, United States

  • CaRe Research, Chubbuck, Idaho, United States

  • Nep Assoc of Northern Illinois, Hinsdale, Illinois, United States

  • Johns Hopkins Hospital, Baltimore, Maryland, United States

  • Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

  • Clin Rsrch Consult a JCCT Company, Kansas City, Missouri, United States

  • DaVita Clinical Research, Las Vegas, Nevada, United States

  • New Jersey Kidney Care, Jersey City, New Jersey, United States

  • Col Uni Med Center New York Presby, New York, New York, United States

  • Dallas Renal Group, Dallas, Texas, United States

  • Novartis Investigative Site, Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site, Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, Santa Fe, Argentina

  • Novartis Investigative Site, Woolloongabba, Queensland, Australia

  • Novartis Investigative Site, Adelaide, South Australia, Australia

  • Novartis Investigative Site, Parkville, Victoria, Australia

  • Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Edegem, Belgium

  • Novartis Investigative Site, Leuven, Belgium

  • Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site, Curitiba, Paraná, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Sao Jose Rio Preto, Brazil

  • Novartis Investigative Site, Temuco, Chile

  • Novartis Investigative Site, Beijing, Beijing Municipality, China

  • Novartis Investigative Site, Beijing, Beijing Municipality, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Luoyang, Henan, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Changsha, Hunan, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Yinchuan, Ningxia, China

  • Novartis Investigative Site, Taiyuan, Shanxi, China

  • Novartis Investigative Site, Xian, Shanxi, China

  • Novartis Investigative Site, Ürümqi, Xinjiang, China

  • Novartis Investigative Site, Ningbo, Zhejiang, China

  • Novartis Investigative Site, Wenzhou, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Guangzhou, China

  • Novartis Investigative Site, Ningbo, China

  • Novartis Investigative Site, Qingdao, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shenzhen, China

  • Novartis Investigative Site, Medellín, Antioquia, Colombia

  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Aalborg, Denmark

  • Novartis Investigative Site, Aarhus N, Denmark

  • Novartis Investigative Site, Copenhagen, Denmark

  • Novartis Investigative Site, Odense C, Denmark

  • Novartis Investigative Site, Marseille, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Stuttgart, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Aachen, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Hanover, Germany

  • Novartis Investigative Site, Kiel, Germany

  • Novartis Investigative Site, Magdeburg, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Tübingen, Germany

  • Novartis Investigative Site, Ulm, Germany

  • Novartis Investigative Site, Hong Kong, Hong Kong, Hong Kong

  • Novartis Investigative Site, Pécs, Baranya, Hungary

  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site, Bangalore, Karnataka, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Hyderabad, Telangana, India

  • Novartis Investigative Site, Ashkelon, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Bologna, BO, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Kasugai, Aichi-ken, Japan

  • Novartis Investigative Site, Toyoake, Aichi-ken, Japan

  • Novartis Investigative Site, Toyota, Aichi-ken, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Kawasaki, Kanagawa, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Kyoto, Kyoto, Japan

  • Novartis Investigative Site, Matsumoto, Nagano, Japan

  • Novartis Investigative Site, Osaka, Osaka, Japan

  • Novartis Investigative Site, Ōmihachiman, Shiga, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Niigata, Japan

  • Novartis Investigative Site, Okayama, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Kuala Lumpur, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Benito Juárez, Mexico City, Mexico

  • Novartis Investigative Site, Querétaro, Mexico

  • Novartis Investigative Site, Groningen, Provincie Groningen, Netherlands

  • Novartis Investigative Site, Nordbyhagen, Oslo, Norway

  • Novartis Investigative Site, Bergen, Norway

  • Novartis Investigative Site, Rostov-on-Don, Russia

  • Novartis Investigative Site, Saint Petersburg, Russia

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Košice, Slovakia

  • Novartis Investigative Site, Ljubljana, Slovenia

  • Novartis Investigative Site, Bloemfontein, Free State, South Africa

  • Novartis Investigative Site, Bundang Gu, Gyeonggi-do, South Korea

  • Novartis Investigative Site, Seoul, Korea, South Korea

  • Novartis Investigative Site, Seoul, Korea, South Korea

  • Novartis Investigative Site, Cheongju-si, North Chungcheong, South Korea

  • Novartis Investigative Site, Seoul, Seoul, South Korea

  • Novartis Investigative Site, Busan, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Taegu, South Korea

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Stockholm, Sweden

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, New Taipei City, Taiwan

  • Novartis Investigative Site, New Taipei City, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site, Köseköy, Kocaeli, Turkey (Türkiye)

  • Novartis Investigative Site, Antalya, Konyaalti, Turkey (Türkiye)

  • Novartis Investigative Site, Kayseri, Melikgazi, Turkey (Türkiye)

  • Novartis Investigative Site, Istanbul, Sariyer, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Mersin, Yenisehir, Turkey (Türkiye)

  • Novartis Investigative Site, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Novartis Investigative Site, Cambridge, United Kingdom

  • Novartis Investigative Site, Leicester, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Salford, United Kingdom

  • Novartis Investigative Site, Ho Chi Minh City, VNM, Vietnam

  • Novartis Investigative Site, Ho Chi Minh City, Vietnam

Study leads
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals